KeyBioscience and Eli Lilly and Co. agreed to work together to develop treatments for type 2 diabetes and other metabolic disorders using KeyBioscience's dual amylin calcitonin receptor agonists platform. Eli Lilly will purchase global rights to the DACRA pipeline, and KeyBioscience will get a $55 million initial payment and is eligible to receive undisclosed milestone payments as well as royalties on future sales.
KeyBioscience's DACRA pipeline bought by Eli Lilly for $55M-plus
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.